Patents Assigned to Astellas Pharma Inc.
  • Patent number: 12161628
    Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: December 10, 2024
    Assignees: Medivation Prostate Therapeutics LLC, Astellas Pharma Inc.
    Inventors: Jacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
  • Publication number: 20240335480
    Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(?) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.
    Type: Application
    Filed: July 14, 2022
    Publication date: October 10, 2024
    Applicants: Astellas Pharma Inc., OSAKA UNIVERSITY, National Center for Child Health and Development
    Inventors: Kenichiro SHIMATANI, Hiromu SATO, Masao SASAI, Yoshiki SAWA, Atsuhiro SAITO, Shigeru MIYAGAWA
  • Publication number: 20240317804
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Application
    Filed: May 10, 2024
    Publication date: September 26, 2024
    Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki ENDO, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
  • Publication number: 20240316115
    Abstract: An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(?) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.
    Type: Application
    Filed: July 14, 2022
    Publication date: September 26, 2024
    Applicants: Astellas Pharma Inc., OSAKA UNIVERSITY
    Inventors: Kenichiro SHIMATANI, Hiromu SATO, Masao SASAI, Yoshiki SAWA, Atsuhiro SAITO, Shigeru MIYAGAWA
  • Patent number: 12097189
    Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.
    Type: Grant
    Filed: March 22, 2024
    Date of Patent: September 24, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Soichiro Nakamura, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Kazuhiro Sako
  • Patent number: 12077519
    Abstract: A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ? (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ? inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.
    Type: Grant
    Filed: November 28, 2023
    Date of Patent: September 3, 2024
    Assignees: Astellas Pharma Inc., KOTOBUKI PHARMACEUTICAL CO., LTD.
    Inventors: Hideyuki Watanabe, Takashi Kamikubo, Akio Kamikawa, Takuya Washio, Yohei Seki, Keiichiro Okuyama, Osamu Ikeda, Hiroshi Tomiyama, Yoshinori Iwai, Akihiko Nakamura, Kozo Miyasaka
  • Patent number: 12065503
    Abstract: Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: August 20, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Jumpei Suemitsu, Megumi Ikeda, Moe Kohno
  • Patent number: 12059409
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.
    Type: Grant
    Filed: March 22, 2024
    Date of Patent: August 13, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Patent number: 12059464
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 13, 2024
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Patent number: 12036315
    Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 16, 2024
    Assignee: Astellas Pharma Inc.
    Inventors: Yoshiaki Umemoto, Takatsune Yoshida, Sachie Namiki, Akira Takagi, Ryo Kojima, Toshiro Sakai, Shinsuke Oba, Hajime Aoki
  • Patent number: 12029797
    Abstract: Provided is a labeled fatty acid derivative for diagnostic imaging that enables quantification of fatty acid metabolic activity in the heart muscle. [Means for Solution] The present inventors have conducted intensive investigations on a method that enables quantification of fatty acid metabolic activity and thus have found that a labeled fatty acid derivative typified by 3-{[(5Z)-3-[18F]fluorotetradeca-5-en-1-yl]sulfanyl}propanoic acid or a salt thereof has excellent accumulation to the heart muscle and thus enables imaging of fatty acid metabolic activity by positron emission tomography (PET). Therefore, the labeled fatty acid derivative of the present invention can be used as a radiolabeled tracer for rapid and non-invasive quantification of fatty acid metabolic activity in the heart muscle, diagnostic imaging of heart disease typified by an ischemic heart disease, diagnostic imaging of the therapeutic effect of a therapeutic drug for heart disease, and the like.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: July 9, 2024
    Assignee: Astellas Pharma Inc.
    Inventors: Yoshihiro Murakami, Hiroshi Fushiki, Yuji Fujita
  • Publication number: 20240209108
    Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki TENDA, Masatoshi YURI, Shigenori YAGI, Yoshiki SATAKE, Kazunori HIRAYAMA, Hiroki SHIRAI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
  • Patent number: 12018095
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: June 25, 2024
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
  • Publication number: 20240180906
    Abstract: This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.
    Type: Application
    Filed: March 21, 2022
    Publication date: June 6, 2024
    Applicants: Pfizer Inc., Astellas Pharma Inc.
    Inventors: Akos Gabor Czibere, Dana Ann Kennedy
  • Publication number: 20240182858
    Abstract: An object of the present invention is to provide a cell therapy that is expected to be useful as an angiogenic therapy for a peripheral vascular disease such as critical lower limb ischemia. Specifically, the object is to provide a pericyte having high angiogenic potential and a method for producing the same. A pericyte introduced a bFGF gene and a method for producing the same are provided.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 6, 2024
    Applicants: Astellas Pharma Inc., Osaka University
    Inventors: Kenichiro SHIMATANI, Hiromu SATO, Masao SASAI, Yoshiki SAWA, Atsuhiro SAITO, Shigeru MIYAGAWA
  • Publication number: 20240164691
    Abstract: An electrocardiogram analysis assistance device (10) including: an analysis waveform acquisition unit (11C) that acquires waveform data in an electrocardiogram for analysis; an analysis waveform select and extract unit (11D) that selects and extracts waveform data of a predetermined first period from the waveform data acquired by the analysis waveform acquisition unit (11C) as analysis divided waveform data; an intermediate information acquisition unit (11I) that acquires intermediate information generated in a middle layer of a peak estimation model (13C) and indicating a shape feature of a peak contained in the analysis divided waveform data by inputting the analysis divided waveform data selected and extracted by the analysis waveform select and extract unit (11D) into the peak estimation model (13C); and a classification unit (11J) that classifies a type of the waveform of the electrocardiogram for analysis using the intermediate information acquired by the intermediate information acquisition unit (11I).
    Type: Application
    Filed: March 23, 2022
    Publication date: May 23, 2024
    Applicant: Astellas Pharma Inc.
    Inventors: Makoto OGINO, Mitsuhisa SHIMIZU, Hideki HASHIMOTO, Toshiya KAGAWA
  • Publication number: 20240166736
    Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.
    Type: Application
    Filed: December 26, 2023
    Publication date: May 23, 2024
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki TENDA, Masatoshi YURI, Daisuke YAMAJUKU, Takeshi TSUTSUMI, Yuko KUSUZAKI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
  • Publication number: 20240164692
    Abstract: An electrocardiogram analysis assistance device (10) including: a peak estimation model (13C) employing waveform data of partial segments of waveform data in an electrocardiogram as input information and employing peak information indicating whether or not a predetermined type of peak related to electrocardiogram analysis is present as output information; an analysis waveform acquisition unit (11C) that acquires waveform data in an electrocardiogram for analysis; an analysis waveform select and extract unit (11D) that selects and extracts waveform data of a predetermined first period from the waveform data acquired by the analysis waveform acquisition unit (11C) as analysis divided waveform data, while each time shifting a predetermined shift period that is a shorter period than the first period; and a derivation unit (11E) that derives the peak information by inputting the analysis divided waveform data selected and extracted by the analysis waveform select and extract unit (11D) into the peak estimation mod
    Type: Application
    Filed: March 23, 2022
    Publication date: May 23, 2024
    Applicant: Astellas Pharma Inc.
    Inventors: Makoto OGINO, Mitsuhisa SHIMIZU, Hideki HASHIMOTO, Toshiya KAGAWA
  • Publication number: 20240150754
    Abstract: An object of the present invention is to provide an antisense guide RNA for editing a polyadenylation signal sequence of a target RNA and a nucleic acid that encodes the guide RNA, which are expected to control expression of the target RNA with high efficiency. The present inventors have intensively examined technologies for controlling expression of a target RNA with high efficiency, thereby completing the present invention by discovering a guide RNA for ADAR-dependent editing of the target RNA, including an antisense region complementary to a portion of the target RNA including a polyadenylation signal sequence.
    Type: Application
    Filed: December 24, 2020
    Publication date: May 9, 2024
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Takatomo ARAI, Mariko MANDA
  • Patent number: 11976130
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: May 7, 2024
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll